Aptevo Therapeutics Hits New 52-Week Low at $1.41

Aptevo Therapeutics, Inc., a player in the Pharmaceuticals & Biotechnology sector, has recently reached a significant milestone by touching a new 52-week low of USD 1.41 on September 15, 2025. This decline highlights the stock's performance amidst a challenging market environment, particularly given its current market capitalization of USD 5 million.
The company's financial metrics reveal a loss-making position, as indicated by the absence of a price-to-earnings (P/E) ratio. Additionally, Aptevo's return on equity stands at a notably low -368.26%, reflecting the company's struggles in generating profit relative to shareholder equity. The stock's price-to-book ratio is recorded at 0.75, suggesting that the market values the company at less than its book value.

With a dividend yield of 0.00%, Aptevo Therapeutics does not currently provide returns to shareholders through dividends. The company's debt-to-equity ratio of -1.44 further emphasizes its financial positioning. The stock's previous 52-week high was significantly higher at USD 381.1, marking a stark contrast to its current valuation.